Business Context and Reporting Period
This Form 8-K Current Report was filed by Alector, Inc. on September 23, 2021. The filing discloses the appointment of Elizabeth A. Garofalo, M.D., to the Company's Board of Directors. Dr. Garofalo was appointed as a Class II director with a term expiring at the 2023 annual meeting of stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and director compensation.
- Director Cash Compensation: $40,000 per fiscal year, payable quarterly in arrears on a pro-rata basis.
- Equity Grant: Option to purchase 33,235 shares of common stock granted on September 23, 2021.
- Vesting Schedule: 25% vests on the one-year anniversary; remaining shares vest monthly (1/48th) thereafter, contingent on continued service.
Material Changes
The primary material change is the expansion of the Board of Directors with the addition of Dr. Garofalo. She brings extensive experience in clinical development and neuroscience leadership, having previously served as Senior Vice President and Global Head of Clinical Development at Novartis and in leadership roles at Astellas and Pfizer. She currently serves on the boards of Acadia Pharmaceuticals, Exicure Inc., and Xenon Pharmaceuticals.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It notes that Dr. Garofalo's option becomes fully vested and exercisable immediately prior to a change in control transaction, provided she remains a service provider. No unusual items or contingencies were disclosed.
Investor Verification Checklist
- Verify the total number of outstanding options granted to non-employee directors to assess potential dilution.
- Confirm Dr. Garofalo's committee assignments once determined by the Board.
- Review the Company's Outside Director Compensation Policy for details on expense reimbursement and future equity award eligibility.
- Check for any subsequent filings regarding the vesting acceleration clauses in the event of a change in control.